

SUPPLEMENTARY MATERIAL

Supplementary Table 1. Symptoms during and after the eruption, by sex and exposure group

	High exposure (Group 1)				Moderate exposure (Group 2)				Minor/no exposure (Group 3)			
	Women		Men		Women		Men		Women		Men	
During the eruption:												
Cough or increase in chronic cough	7	36.8%	19	54.3%	89	38.7%	39	38.2%	11	20.4%	6	19.4%
Difficulty breathing	5	26.3%	14	40.0%	85	37.0%	22	21.6%	6	11.1%	4	12.9%
Tightness in the chest	6	31.6%	10	28.6%	84	36.5%	24	23.5%	3	5.6%	1	3.2%
Headache	8	42.1%	21	60.0%	128	55.7%	37	36.3%	18	33.3%	5	16.1%
Itchy/burning nose	12	63.2%	17	48.6%	130	56.5%	45	44.1%	20	37.0%	13	41.9%
Nasal congestion	9	47.4%	23	65.7%	101	43.9%	50	49.0%	13	24.1%	8	25.8%
Itchy/burning throat	11	57.9%	25	71.4%	135	58.7%	51	50.0%	17	31.5%	8	25.8%
Sore throat	0	0.0%	15	42.9%	69	30.0%	22	21.6%	8	14.8%	5	16.1%
Itchy/stinging eyes	12	63.2%	28	80.0%	171	74.3%	65	63.7%	29	53.7%	13	41.9%
Watery burning eyes	9	47.4%	19	54.3%	94	40.9%	38	37.3%	14	25.9%	6	19.4%
Skin problems	7	36.8%	9	25.7%	58	25.2%	19	18.6%	6	11.1%	2	6.5%
After the eruption:	0		0		0		0		0		0	
Cough or increase in chronic cough	8	42.1%	14	40.0%	85	37.0%	39	38.2%	13	24.1%	4	12.9%
Difficulty breathing	5	26.3%	4	11.4%	49	21.3%	18	17.6%	3	5.6%	0	0.0%
Tightness in the chest	2	10.5%	9	25.7%	65	28.3%	15	14.7%	3	5.6%	1	3.2%
Headache	8	42.1%	11	31.4%	107	46.5%	23	22.5%	18	33.3%	2	6.5%
Itchy/burning nose	11	57.9%	11	31.4%	91	39.6%	29	28.4%	11	20.4%	8	25.8%
Nasal congestion	8	42.1%	14	40.0%	92	40.0%	36	35.3%	14	25.9%	10	32.3%
Itchy/burning throat	8	42.1%	13	37.1%	101	43.9%	39	38.2%	11	20.4%	4	12.9%
Sore throat	3	15.8%	8	22.9%	57	24.8%	23	22.5%	8	14.8%	3	9.7%
Itchy/stinging eyes	9	47.4%	16	45.7%	101	43.9%	37	36.3%	18	33.3%	6	19.4%
Watery burning eyes	6	31.6%	10	28.6%	49	21.3%	19	18.6%	10	18.5%	3	9.7%
Skin problems	4	21.1%	5	14.3%	52	22.6%	9	8.8%	6	11.1%	2	6.5%

Symptoms in which there are statistically significant differences are shown in red.

Supplementary Table 2. Adjusted logistic regression of the prebronchodilator lung function measures by exposure group.

	FEV1<80%		FVC <80%		FEV1/FVC <70%		DLCO<80%	
	OR	CI95%	OR	CI95%	OR	CI95%	OR	CI95%
Group 1	1,4	0,3- 5,6	1,3	0,2-,6	1,9	0,5-6,7	2,9	0,6-14,7
Group 2	1,7	0,7- 4,4	2,2	0,7-6,4	1,4	0,5-3,6	-	-
Group 3 (reference)	1	-	1	-	1	-	1	-

*Adjusted by age, sex, smoking and Charlson comorbidity index. OR: Odds ratio; IC95%:

Supplementary Table 3. Summary of postbronchodilator spirometry parameters and percentage of subjects with abnormal values.


	Total	Group 1	Group 2	Group 3	p-value
	n= 102	n= 20	n= 77*	n= 5	
FEV1 (%)					
Median (P25-P75)	103 (91-110)	99.5 (91-108)	105 (92-112)	88 (83-95)	0.624
FEV1 <80% (n, %)	11 (10.8%)	2 (10.0%)	9 (11.7%)	0	0.933
FVC (%)					
Median (P25-P75)	102 (93-112)	101 (94.5-110)	104 (94-114)	91 (90-94)	0.910
FVC <80% (n, %)	6 (6.0%)	0	6 (8.0%)	0	-
FEV1/FVC (%)					
Median (P25-P75)	80.4 (71.7-84.7)	80.3 (71.9-84.7)	80.4 (71.8-84.9)	73.5 (70.5-80.5)	0.998
FEV1/FVC <70% (n, %)	51 (51.0%)	10 (50.0%)	39 (52.0%)	2 (40.0%)	0.972

P: percentile. *2 Missing FVC and FEV1/FVC values.


Supplementary Table 4. Spirometry patterns with pre- and postbronchodilator values, overall and by exposure group.

	Total	High exposure (Group 1)	Moderate exposure (Group 2)	No exposure (Group 3)
	N=474	N=54	N=335	N=85
Spirometry patterns with prebronchodilator values				
Obstructive				
<i>FEV1pre<80% and FEV1/FVCpre<70%</i>	16 (3.4%)	3 (5.6%)	10 (3.0%)	3 (3.5%)
PRISm				
<i>FEV1pre≥80% and FEV1/FVCpre<70%</i>	13 (2.7%)	1 (1.9%)	7 (2.1%)	5 (5.9%)
Desynapsis				
<i>FEV1pre≥80% and FEV1/FVCpre<70%</i>	25 (5.3%)	4 (7.4%)	18 (5.4%)	3 (3.5%)
Spirometry restriction				
<i>FVCpre<80% and FEV1/FVCpre≥70%</i>	16 (3.4%)	1 (1.9%)	8 (2.4%)	7 (8.2%)
Mixed				
<i>FVCpre<80% and FEV1/FVCpre<70%</i>	4 (0.8%)	1 (1.9%)	3 (0.9%)	0 (0.0%)
Spirometry patterns with postbronchodilator values				
	N=100	N=20	N=77*	N=3
Obstructive				
<i>FEV1post<80% and FEV1/FVCpost<70%</i>	7 (1.5%)	2 (3.7%)	5 (1.5%)	0 (0.0%)
PRISm				
<i>FEV1post<80% and FEV1/FVCpost≥70%</i>	4 (0.8%)	0 (0.0%)	4 (1.2%)	0 (0.0%)
Desynapsis				
<i>FEV1post≥80% and FEV1/FVCpost<70%</i>	11 (2.3%)	2 (3.7%)	8 (2.4%)	1 (1.2%)
Spirometry restriction				
<i>FVCpost<80% and FEV1/FVCpost≥70%</i>	4 (0.8%)	0 (0.0%)	4 (1.2%)	0 (0.0%)
Mixed				
<i>FVCpost<80% and FEV1/FVCpost<70%</i>	2 (0.4%)	0 (0.0%)	2 (0.6%)	0 (0.0%)


*2 Missing values. Subjects were categorized by spirometry pattern: Obstructive: FEV1 <80%, FEV1/FVC<70%; PRISm (Preserved Ratio of Impaired Spirometry): FEV1 <80%, FEV1/FVC≥70%; Desynapsis: FEV1≥80%, FEV1/FVC<70%; Spirometry restriction: FVC<80%, FEV1/FVC≥70%; Mixed: FVC<80%, FEV1/FVC<70%.



Supplementary Figure 1. Degree of dyspnea according to the mMRC questionnaire, by sex.



Supplementary Figure 2. Number of symptoms before and after the eruption, by sex.



Supplementary Figure 3. Lung function (postbronchodilator FEV1/FVC) by sex.